Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

BGB-11417-102 (NCT04883957) is a Phase 1 trial of sonrotoclax in adult patients with mature B-cell malignancies.

BGB-11417-102 (NCT04883957) is a Phase 1 trial of sonrotoclax in adult patients with mature B-cell malignancies.